Clinilabs Selected for a Phase I/II Study of HIV Vaccine
Clinilabs announced that they have been selected to conduct a Phase I/II clinical research study of an investigational vaccine for HIV.
According to Dr. Howard Greenberg, Senior Medical Director of Clinilabs, "Conducting early phase clinical trials with a novel therapeutic in a new patient population is a major advance in Clinilabs’ progression as a CRU.”
Greenberg also notes that conducting vaccine studies and expanding enrollment of specialty patient populations are two key strategic directions Clinilabs is pursuing to capitalize on its position as a global CRO that operates a CRU in New York City, a hub of academic medical centers and home to a diverse population of more than 19 million potential research subjects.
Enrollment for this study is expected to begin later this month.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
